IEInas El‐Najjar

Inas El‐Najjar

*This is an algorithmically generated author record based on publicly available information.

Inas El‐Najjar has a total of 44 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The cumulative effect of cytogenetic abnormalities on the outcomes of myeloma patients with del(17p) undergoing AHSCT in EBMT centres between 2016 and 2022

    by Claire Comerford, Patrick J. Hayden, Diderik‐Jan Eikema, Linda Koster, Sandra Sauer, Annoek Broers, Neil Rabin, Jean Noel Bastie, Tobias Gedde‐Dahl, Luisa Giaccone, et al.

  • Platelet loss during hematopoietic progenitor cell apheresis: Predictive factors and clinical implications in G-CSF-mobilized donors

    by Yandy Marx Castillo-Aleman, Shinnette Lumame, Jay Mary Rose-Roque, Marlene Cato, Ruaa Mousa Ali, Aseel Suleiman Alsaid, Sakher Ahmad Obeidat, Mansi Sachdev, Jayakumar David Dennison, Inas El-Najjar, et al.

  • Citrate Versus Citrate–Heparin Anticoagulation in HPC (A): Comparative Effects on Intra‐Apheresis Mobilization of CD34 + Hematopoietic Progenitor Cells

    by Yandy Marx Castillo‐Aleman, Carlos Agustin Villegas‐Valverde, Antonio Alfonso Bencomo‐Hernandez, Shinnette Lumame, Charisma Castelo, Jay Mary Rose‐Roque, Marlene Cato, Nameer Al‐Saadawi, Mohamed Ibrahim Abu‐Haleeqa, Aseel Suleiman Alsaid, et al.

    Successful hematopoietic stem cell transplantation relies on the collection of a sufficient number of CD34 + hematopoietic progenitor cells (HPCs). While acid citrate dextrose solution A (ACD‐A) is a common anticoagulant (AC) for HPC apheresis [HPC(A)], recent evidence suggests that concomitant heparin may enhance intra‐apheresis recruitment (IAR) of CD34 + cells and improve collection efficiency. This study aimed to compare citrate‐only and citrate–heparin protocols in routine HPC(A) procedures, with a focus on their effects on IAR and efficiency outcomes. A retrospective analysis was performed on 266 HPC(As) from 193 apheresis donors in autologous and allogeneic settings. Donor demographics, procedural parameters, and collection outcomes were compared between the ACD‐A–only and ACD‐A plus heparin protocols. The study endpoints included apheresis yield (AY/kg), collection efficiencies (CE 1 , CE 2 , and cruCE), recruitment ratio (RR), and performance ratio (PR). Statistical analyses included Mann–Whitney U tests, effect sizes, and partial least squares (PLS) regression. Heparinized procedures demonstrated higher processed total blood volume ratios, lower AC volumes, and superior outcomes across CE 1 (83.8% vs. 72.5%, p = 0.00027), CE 2 (70.8% vs. 64.2%, p = 0.0055), cruCE (77.0% vs. 72.4%, p < 0.0001), RR (2.3 vs. 1.7, p < 0.0001), PR (239.3% vs. 208.2%, p < 0.0001), and AY/kg (6.75 vs. 5.23 × 10 6 CD34 + cells/kg, p = 0.0025). The effect size and PLS analyses confirmed the contribution of heparin as an adjunct AC enhancing multiple apheresis outcomes. In summary, citrate–heparin anticoagulation was found to be a feasible strategy that improved key collection efficiency and IAR metrics during HPC(A).

  • The Day Two Advantage: A Retrospective Paired Analysis of Consecutive HPC(A) Collections

    by Yandy Marx Castillo‐Aleman, Carlos Agustin Villegas‐Valverde, Antonio Alfonso Bencomo‐Hernandez, Shinnette Lumame, Charisma Castelo, Jay Mary Rose‐Roque, Marlene Cato, Nameer Al‐Saadawi, Mohamed Ibrahim Abu‐Haleeqa, Inas El‐Najjar, et al.

    The hematopoietic progenitor cell apheresis [HPC(A)] is a cornerstone of stem cell transplantation. While multiple apheresis sessions are common in clinical practice, few studies have examined the procedural variability within the same donor across consecutive collections. This study aims to compare changes in the efficiency metrics between the first and second HPC(A) procedures. A retrospective analysis was conducted on paired HPC(A) procedures performed on the same donor between January 2023 and May 2025 at the Abu Dhabi Stem Cells Center. The predefined parameters, including the collection efficiencies (CE1, CE2, cruCE), performance ratio (PR), and total volume processed (TVP), were compared using the Wilcoxon signed‐rank tests. Effect sizes were calculated using Cohen's r, and associations between variables were assessed using the Spearman correlation. Of the 215 procedures screened, 90 met the inclusion criteria. Despite similar preapheresis CD34+ cell counts and flow rates, second‐day procedures demonstrated significantly improved CE1, CE2, and PR, with lower TVP. A large effect size was observed for the TVP/total blood volume (TBV) ratio (r = 0.63), and moderate‐to‐large effect sizes for CE2 (r = 0.41), PR (r = 0.47), and CE1 (r = 0.47). CE1 and CE2 correlated strongly with PR across both sessions, while CE2 correlated positively with TVP/TBV on day 1 (ρ = 0.47) and negatively on day 2 (ρ = −0.40). Second‐day HPC(A) sessions yielded superior efficiency despite reduced volume, supporting the value of individualized collection planning. These “day two advantages” may inform refinements in yield prediction and highlight the need for prospective studies to optimize apheresis strategies.


  • Green Plasma in Extracorporeal Photopheresis: A Case Report in Overlap Chronic GvHD

    by Yandy Marx Castillo‐Aleman, Aseel Suleiman Alsaid, Shinnette Lumame, Charisma Castelo, Jay Mary Rose Roque, Marlene Cato, Yara Khaled Afifi, Sheima Ali, Mohamed Ibrahim Abu‐Haleeqa, Inas El‐Najjar, et al.

    We report the case of a 50‐year‐old male with peripheral T‐cell lymphoma who underwent allogeneic hematopoietic stem cell transplantation and developed overlap chronic graft‐versus‐host disease (ocGvHD) requiring extracorporeal photopheresis (ECP). His clinical presentation included a maculopapular rash with jaundice, hepatosplenomegaly, hyperbilirubinemia, and elevated liver enzymes. Liver biopsy findings were not consistent with GvHD or lymphoma but were suggestive of drug‐induced hepatitis. ECP was initiated using the Therakos CellEx Photopheresis System. During the initial sessions, dark green plasma discoloration was observed, accompanied by multiple plasma/red blood cell interface‐related procedural alarms. These challenges were managed through various operator adjustments, and the procedures remained safe and effective. Over four ECP sessions, both the discoloration and opacity of the plasma progressively improved, in parallel with declining liver enzyme levels and a reduction in procedural alarms. This temporal association between hepatic recovery and improved interface stability during ECP has not been previously described in the context of ocGvHD. Although dark green plasma is an uncommon finding in this setting, it should prompt evaluation for underlying hepatic dysfunction and timely management of plasma/red blood cell interface issues to ensure safe and effective ECP delivery.